Related Experiment Video
Updated: May 20, 2025

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and
Insights
Acetaminophen (APAP) use remained stable in US children with cancer, but APAP-opioid combination prescriptions decreased nationally, with regional variations. Further research is needed to assess APAP exposure and liver health in this population.
Area of Science:
- Pediatric Oncology
- Pharmacology
- Public Health
Background:
- Acetaminophen (APAP) is a common analgesic and antipyretic in children, including those with cancer in the United States (US).
- Previous studies evaluated US Food & Drug Administration (FDA) guidance on APAP prescribing in healthy children and adults, but patterns in pediatric cancer patients were unknown.
- Children with cancer face heightened risks of liver injury, making APAP use patterns critical to understand.
Purpose of the Study:
- To examine the recent trends in acetaminophen (APAP) prescribing among children with cancer in the United States.
- To analyze the evolution of APAP and APAP-opioid combination use in this vulnerable population.
- To provide insights into pain management strategies and analgesic exposure in pediatric cancer patients.
Main Methods:
- A retrospective, multi-center analysis of APAP prescribing data from the Pediatric Health Information System (PHIS) database.
- Inclusion criteria: children aged 0-26 years with a cancer diagnosis (ICD codes) receiving chemotherapy.
- Assessment of APAP and APAP-opioid combination prescribing rates at national, regional, and hospital levels using the Mann-Kendall test.
Main Results:
- Data from 2004-2021 included 388,364 inpatient encounters for 50,779 unique patients; 87.3% received APAP.
- APAP-opioid combination use was infrequent but more likely among patients receiving APAP (13.4%).
- National APAP use was stable; regional APAP use increased in the Northeast. APAP-opioid combination use decreased nationally, with consistently elevated use in the South before 2014.
Conclusions:
- Acetaminophen (APAP) prescribing trends in children with cancer show national stability in APAP use but a decline in APAP-opioid combinations, albeit with regional differences.
- These findings are crucial for clinicians to evaluate evolving pain management strategies and analgesic exposure in pediatric cancer patients.
- Further research is warranted to assess the impact of APAP exposure on liver health in children undergoing cancer treatment.
Purpose:
Acetaminophen ( APAP ) is a ubiquitous antipyretic and analgesic used in children in the United States ( US ), including those with cancer. The effects of US Food & Drug Administration ( FDA ) guidance on APAP prescribing have been described for healthy adults and children; however, APAP use patterns in children with cancer are unknown. Considering their increased risk of liver injury, APAP's potential for causing hepatoxicity, and FDA guidance changes, this study examined the recent evolution of APAP use in children with cancer.
Methods:
This retrospective, multi-center analysis extracted APAP prescribing data from the Pediatric Health Information System® ( PHIS ). Eligible children were aged 0-26 years, had a cancer diagnosis per International Classification of Diseases ( ICD ) codes, and were prescribed a chemotherapeutic. APAP and APAP-opioid combination prescribing were assessed at hospital, regional, and national levels. Changes in APAP and APAP-opioid combination use rates were assessed using the non-parametric Mann-Kendall test.
Findings:
PHIS records for the complete years of 2004-2021 yielded 388,364 inpatient encounters for 50,779 unique patients. Of these, 87.3% of patients received APAP. Although APAP-opioid combination use was infrequent overall, children receiving APAP were more likely to receive an APAP-opioid combination medication (N=25,880, 13.4%, p < 0.001) compared to those who did not receive APAP. Among specialty children's hospitals, national APAP use was stable over the study period. Regionally, APAP use increased among hospitals in the Northeast. APAP-opioid combination use decreased nationally with regional variation. In contrast to the steady decline in other regions, Southern APAP-opioid combination use was consistently elevated before declining in 2014.
Implications:
This article describes acetaminophen and acetaminophen-opioid prescribing trends among children with cancer in the United States. These trends are key to help clinicians assess changes in pain management strategies over time, contextualize analgesic exposure and efficacy, and provide a foundation for future studies in drug safety. Extensive acetaminophen use can affect liver health, and further work is needed to evaluate acetaminophen exposure in children with cancer.
Data Statement:
Deidentified data were obtained and evaluated under an IRB-approved protocol. Due to privacy requirements, the data are not available to be shared.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Factors Affecting Drug Response: Overview
Combined Effects of Drugs: Synergism
Such synergistic combinations...